Skip to main content
MAJI
OTC Technology

Amended Regulation A Offering: Massive Dilution at Discounted Price to Fund Operations

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.044
Mkt Cap
$1.938M
52W Low
$0.015
52W High
$0.32
52W Position info
193% above low
Off High info
86% below high
Rel. Volume
Market data snapshot near publication time

MAJI has more than doubled off its 52-week low of $0.015.

Summary

Exousia Pro, Inc. amended its Regulation A offering, proposing to sell up to 50 million shares and allow selling shareholders to offer 15 million shares at $0.03 per share, significantly below the current market price, leading to substantial potential dilution.


Key Events · Financing and Capital Events · MAJI

  • Expanded Regulation A Offering

    The company is offering up to 50,000,000 shares, and selling shareholders are offering up to 15,000,000 shares, for a total of 65,000,000 shares.

  • Discounted Offering Price

    All shares are offered at $0.03 per share, representing a significant discount to the current market price of $0.044.

  • Massive Potential Dilution

    If all remaining shares are issued, existing shareholders face potential dilution of approximately 139%.

  • Critical Capital Raise for Going Concern

    The company has accumulated losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern, making this offering crucial for funding operations and R&D.


Analysis · MAJI · Technology

Exousia Pro, Inc. filed an amendment to its Regulation A offering, significantly increasing the number of shares available for sale by both the company and selling shareholders. The company aims to raise up to $1.5 million by offering 50 million shares, while selling shareholders may offer an additional 15 million shares, all at a price of $0.03 per share. This offering price is at a substantial discount to the current market price of $0.044. If all shares are issued, existing shareholders face potential dilution of approximately 139%. The proceeds for the company are earmarked for critical needs including investigational new drug trials, product development, and working capital, highlighting the company's precarious financial position, which includes a 'going concern' warning. This capital raise is essential for the company's continued operations but comes at a significant cost to current shareholders.

At the time of this filing, MAJI was trading at $0.04 on OTC in the Technology sector, with a market capitalization of approximately $1.9M. The 52-week trading range was $0.02 to $0.32. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MAJI - Latest Insights

MAJI
Jul 22, 2026, 12:16 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.0084
Real-time Price: $0.0085 info
Change: +$0.0001 (+1%) info
Market Cap: $722.381K info
MAJI
Mar 27, 2026, 3:12 PM EDT
Filing Type: 253G1
Importance Score:
9
Price at Filing: $0.0429
Real-time Price: $0.0085 info
Change: -$0.0344 (-80%) info
Market Cap: $722.381K info
MAJI
Mar 20, 2026, 4:23 PM EDT
Filing Type: 1-A POS
Importance Score:
9
Price at Filing: $0.037
Real-time Price: $0.0085 info
Change: -$0.0285 (-77%) info
Market Cap: $722.381K info
MAJI
Mar 16, 2026, 10:15 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $0.0299
Real-time Price: $0.0085 info
Change: -$0.0214 (-72%) info
Market Cap: $722.381K info
MAJI
Mar 11, 2026, 3:11 PM EDT
Filing Type: 1-A POS
Importance Score:
9
Price at Filing: $0.02162
Real-time Price: $0.0085 info
Change: -$0.01312 (-61%) info
Market Cap: $722.381K info